Amer Zeidan, Professor of Medicine, Chief of Hematologic Malignancies, Director of Heme Clinical Research at Yale University, shared a post on X:
“I look forward to this very important presentation in EHA 2026 about value of transplant in TP53 mutated MDSsm and AMLsm.
The results clearly indicate a tail at end of curve and around 20% 23-year OS even among biallelic TP53mut patients, and especially in those with lower blast counts. Do NOT deprive patients from the opportunity of transplant without a very well-informed discussion!
Patients with KPS >80 had an estimated 3-year OS of 49.3%, compared with 30.2% for KPS ≤80.
Biallelic TP53 was associated with inferior survival (HR 4.05, 95% CI 1.76–9.32; p=0.001) (figure 1b), reaching statistical significance only in the MDS subgroup.A low blast count at diagnosis was associated with improved survival (HR 0.50, 95% CI 0.29–0.88; p=0.02).
No clear associations were observed for age, HCT-CI, donor type, conditioning intensity or ATG. NRM did not differ significantly between MDS and AML (figure 1c).
ALLOGENEIC HSCT FOR TP53-ABERRANT MYELOID NEOPLASMS: REAL-WORLD… – Myhre A – EHA-6995 – Jun 13 2026.”
Other articles featuring Amer Zeidan on OncoDaily.